Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.684025
Keywords
mesothelioma; genomics; transcriptomics; immune; checkpoint; microenvironment
Categories
Ask authors/readers for more resources
Malignant pleural mesothelioma is a rare and aggressive malignancy with limited treatment options, although immune checkpoint inhibition has shown some efficacy in a small subset of patients. Advances in next-generation sequencing technology have provided a better understanding of the molecular characteristics of MPM and its impact on the immune microenvironment.
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options beyond surgery and cytotoxic chemotherapy. The success of immune checkpoint inhibition has been found to correlate with expression of immune-related genes such as CD274 (PD-L1) in lung and other solid cancers. However, only a small subset of MPM patients respond to checkpoint inhibition, and this response has been varied and unpredictable across several clinical trials. Recent advances in next-generation sequencing (NGS) technology have improved our understanding of the molecular features of MPM, also with respect to its genetic signature and how this impacts the immune microenvironment. This article will review current evidence surrounding the interplay between MPM genetics, including epigenetics and transcriptomics, and the immune response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available